According to a recent LinkedIn post from Neuromod Devices Ltd, the company is participating in the 2026 Joint Defense Veterans Audiology Conference (JDVAC) at the DoubleTree by Hilton in Orlando, Florida, where it is present at Booth 11. The post highlights Lenire, described as the first and only FDA-approved bimodal neuromodulation device for tinnitus, and emphasizes its availability as a treatment option for approximately 3.2 million U.S. veterans through the Department of Veterans Affairs.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Neuromod is actively targeting the U.S. veterans’ healthcare segment, a sizable and specialized patient population with chronic tinnitus needs. For investors, visibility at JDVAC and integration into the VA treatment ecosystem may indicate a pathway to recurring reimbursement-driven revenue, strengthen clinical adoption among audiologists and otolaryngologists, and reinforce the company’s competitive positioning in the tinnitus and hearing-care market.